Cardiac Safety Profile of Imatinib and Nilotinib In Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia In Chronic Phase (CML-CP): Results From ENESTnd.

被引：0
|
作者：
Larson, Richard A. [1 ]
Hochhaus, Andreas [2 ]
Saglio, Giuseppe [3 ]
Rosti, Gianantonio [4 ]
Lopez, Jose L. [5 ]
Stenke, Leif [6 ,7 ]
Nakamae, Hirohisa [8 ]
Goldberg, Stuart L. [9 ]
Wang, Ming-Chung [10 ]
Gallagher, Neil J. [11 ]
Hoenekopp, Albert [11 ]
Ortmann, Christine-Elke
Hughes, Timothy P. [12 ]
Kantarjian, Hagop M. [13 ]
机构：
[1] Univ Chicago, Med Ctr, Chicago, IL 60637 USA
[2] Univ Klinikum Jena, Klin Innere Med 2, Jena, Germany
[3] Univ Turin, Div Internal Med & Hematol, Orbassano, Italy
[4] Univ Bologna, Dept Hematol Oncol, Bologna, Italy
[5] Banco Municipal Sangre, Dpt Clin Hematol, Caracas, Venezuela
[6] Karolinska Univ Hosp, Div Hematol, Stockholm, Sweden
[7] Karolinska Inst, Stockholm, Sweden
[8] Osaka City Univ, Grad Sch Med, Osaka 558, Japan
[9] Hackensack Univ, Med Ctr, John Theurer Canc Ctr, Div Leukemia, Hackensack, NJ USA
[10] Chang Gung Mem Hosp, Kaohsiung Med Ctr, Dept Internal Med, Kaohsiung, Taiwan
[11] Novartis Pharma AG, Oncol, Basel, Switzerland
[12] Royal Adelaide Hosp, Dept Haematol SA Pathol, Adelaide, SA 5000, Australia
[13] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
BLOOD | 2010年 / 116卷 / 21期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：944 / 945
页数：2
相关论文
共 50 条
  • [21] Nilotinib in Elderly Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: Efficacy and Safety Analysis
    Lipton, Jeffrey H.
    le Coutre, Philipp D.
    Wang, Jim
    Yang, Mindy
    Szczudlo, Tomasz
    Giles, Francis
    BLOOD, 2008, 112 (11) : 1110 - 1110
  • [22] Nilotinib Versus Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph+) Chronic Myeloid Leukemia in Chronic Phase (CML-CP): ENESTnd 36-Month (mo) Follow-up
    Saglio, Giuseppe
    LeCoutre, Philipp D.
    Pasquini, Ricardo
    Jootar, Saengsuree
    Nakamae, Hirohisa
    Flinn, Ian W.
    Hochhaus, Andreas
    Hughes, Timothy P.
    Larson, Richard A.
    Hoenekopp, Albert
    Gallagher, Neil J.
    Yu, Richard
    Blakesley, Rick E.
    Kim, Dong-Wook
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 208 - 209
  • [23] Enestnd 4-Year (y) Update: Continued Superiority of Nilotinib Vs Imatinib in Patients (pts) with Newly Diagnosed Philadelphia Chromosome-Positive (Ph plus ) Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Kantarjian, Hagop M.
    Kim, Dong-Wook
    Issaragrisil, Surapol
    Clark, Richard E.
    Reiffers, Josy
    Nicolini, Franck E.
    Pasquini, Ricardo
    Kalaycio, Matt
    Hughes, Timothy P.
    Hochhaus, Andreas
    Kemp, Charisse
    Fan, Xiaolin
    Waltzman, Roger J.
    Saglio, Giuseppe
    Larson, Richard A.
    BLOOD, 2012, 120 (21)
  • [24] EFFICACY AND SAFETY OF NILOTINIB IN OLDER (≥65 YEARS) PATIENTS WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): RESULTS FROM THE PHASE 3 ENESTND (EVALUATING NILOTINIB EFFICACY AND SAFETY IN CLINICAL TRIALS OF NEWLY DIAGNOSED PHILADELPHIA CHROMOSOME-POSITIVE CML PATIENTS) STUDY.
    Gorospe, Gerry
    Kantarjian, H. Hagop
    Hochhaus, Andreas
    Larson, Richard
    Saglio, Giuseppe
    Hughes, Timothy
    ONCOLOGY NURSING FORUM, 2012, 39 (03) : E191 - E192
  • [25] Detection of new mutations in patients (pts) with imatinib-resistant chronic myeloid leukemia in chronic phase (CML-CP) treated with nilotinib.
    Hochhaus, A.
    Saglio, A.
    Kantarjian, H.
    Haque, A.
    Shou, Y.
    Woodman, R. C.
    Hughes, T. P.
    Radich, J. P.
    Martinelli, G.
    Kim, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [26] COMPARATIVE EFFICACY OF IMATINIB, DASATINIB AND NILOTINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): A META-ANALYSIS AND INDIRECT COMPARISON
    Park, J.
    Kwon, H.
    Shin, M.
    Shin, S.
    Lee, J. Y.
    VALUE IN HEALTH, 2015, 18 (07) : A433 - A433
  • [27] Watching To Nilotinib In Patients (pts) With Chronic Myeloid Leukemia In Chronic Phase (CML-CP) With Suboptimal Cytogenetic Response (CyR) On Imatinib: First Results Of The LASOR Trial
    Cortes, Jorge E.
    De Souza, Carmino Antonio
    Lopez, Jose Luis
    Ayala, Manuel
    Bullorsky, Eduardo
    Huang, Xiaojun
    Shah, Sandip
    Babu, K. Govind
    Sacha, Tomasz
    Bendit, Israel
    Liang, Zhizhou
    Owugah, Tina
    Nidamarthy, Prasanna Kumar
    Szczudlo, Tomasz
    Piccolo, Carmen
    le Coutre, Philipp D.
    BLOOD, 2013, 122 (21)
  • [28] Deep Molecular Response in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated With Nilotinib: ENESTnext Update
    Mauro, Michael J.
    Dakhil, Shaker
    Cortes, Jorge E.
    Rizzieri, David A.
    Keir, Christopher H.
    Yi, Sandy
    Heinrich, Michael C.
    Goldberg, Stuart L.
    Catchatourian, Rosalind
    Kuriakose, Philip
    Radich, Jerald P.
    BLOOD, 2014, 124 (21)
  • [29] Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Hochhaus, Andreas
    Saglio, Giuseppe
    Hughes, Timothy P.
    Larson, Richard A.
    Taningco, Lilia
    Deng, Weiping
    Menssen, Hans D.
    Kantarjian, Hagop M.
    BLOOD, 2015, 126 (23)
  • [30] Efficacy and Safety of Nilotinib In Chronic Phase (CP) Chrome Myeloid Leukemia (CML) Patients (Pts) with Type 2 Diabetes In the ENESTnd Trial
    Saglio, Giuseppe
    Larson, Richard A.
    Hughes, Timothy P.
    Issaragrisil, Surapol
    Turkina, Anna G.
    Marin, David
    Zanichelli, Maria
    Shibayama, Hirohiko
    Kalaycio, Matt E.
    Rigal-Huguet, Francoise
    Gallagher, Neil J.
    Kayath, Marcia
    Zheng, Ming
    Kantarjian, Hagop
    Hochhaus, Andreas
    BLOOD, 2010, 116 (21) : 1405 - 1406
12345